First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of...

テリックスと日本メジフィジックスが アクチニウム標識腎癌治療薬の開発を目指した技術提携契約を締結 MELBOURNE, Australia, KYOTO, Japan and TOKYO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited（本社：オーストラリア メルボルン、CEO：Dr. Christian...

Telix and Nihon Medi-Physics to Collaborate on Actinium Renal Cancer Therapeutics MELBOURNE, Australia, KYOTO, Japan and TOKYO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused...

Telix Pharmaceuticals, University of Melbourne and Peter Mac to Collaborate on Colorectal Cancer MELBOURNE, Australia, Aug. 24, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”) has today announced a research collaboration with the University of Melbourne...